Treatment of acute myeloid leukemia: are we making progress?
暂无分享,去创建一个
[1] E. Estey,et al. Gemtuzumab ozogamicin: time to resurrect? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] H. Dombret,et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study , 2012, The Lancet.
[3] W. Jędrzejczak,et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] N. Socci,et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.
[5] Y. Min,et al. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. , 2011, Blood.
[6] Robert K Hills,et al. Applicability of a "Pick a Winner" trial design to acute myeloid leukemia. , 2011, Blood.
[7] T. Naoe,et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. , 2011, Blood.
[8] R. Hills,et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] B. Löwenberg,et al. Therapeutic advances in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Hills,et al. Independent prognostic variables in acute myeloid leukaemia. , 2011, Blood reviews.
[11] R. Hills,et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Bourhis,et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Gabrilove,et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] R. Hills,et al. Attempts to Optimise Induction and Consolidation Chemotherapy in Patients with Acute Myeloid Leukaemia: Results of the MRC AML15 Trial. , 2009 .
[15] H. Döhner,et al. High-dose daunorubicin in older patients with acute myeloid leukemia. , 2009, The New England journal of medicine.
[16] Hisashi Sakamaki,et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. , 2009, JAMA.
[17] Keith Wheatley,et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials , 2009, British journal of haematology.
[18] R. Hills,et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial , 2009, British journal of haematology.
[19] Sören Lehmann,et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. , 2009, Blood.
[20] M. Patnaik,et al. Anthracycline dose intensification in acute myeloid leukemia. , 2009, The New England journal of medicine.
[21] Axel Benner,et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.
[22] I. Seferyńska,et al. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome—Polish Adult Leukemia Group (PALG) pilot study , 2008, Annals of Hematology.
[23] M. Sorror,et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. , 2007, Blood.
[24] Augustin Ferrant,et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? , 2007, Blood.
[25] H. Kantarjian,et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. , 2007, British journal of haematology.
[26] R. Hills,et al. A Sensitive Risk Score for Directing Treatment in Younger Patients with AML. , 2006 .
[27] E. Estey,et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. , 2006, Blood.
[28] Debra Speert,et al. Pick a winner , 2006 .
[29] E. Estey,et al. Clinical Relevance of CRp in Untreated AML. , 2005 .
[30] R. Hills,et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. , 2005, Blood.
[31] D. Scheinberg,et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] F. Mandelli,et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. , 2004, Blood.
[33] I. Bernstein,et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin) , 2002, Leukemia.
[34] R. Gray,et al. A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial , 1999, British journal of haematology.
[35] M. Grever,et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. , 1996, Blood.
[36] O. Garson,et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. , 1996, Blood.
[37] R. Mayer,et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.
[38] J. Matthews,et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. , 1990, Blood.
[39] Nathan Mantel,et al. Evaluation of Response-Time Data Involving Transient States: An Illustration Using Heart-Transplant Data , 1974 .